Biogen ''committed'' to ALS despite dexpramipexole Phase III failure
This article was originally published in Scrip
Executive Summary
Biogen Idec has disclosed no other amyotrophic lateral sclerosis (ALS) drugs in its clinical pipeline, but when the company said that it would discontinue development of dexpramipexole after the ALS therapy missed the primary endpoint in a Phase III clinical trial, executive vice-president of research and development Douglas Williams said Biogen would continue its work with outside scientists "to understand the causes of ALS and find potential treatments".
You may also be interested in...
Finance Watch: Big Money For Private Biopharma As Start-Up Areteia Raises $350m
Private Company Edition: As venture capital funding continues at a robust pace relative to public company financings, Knopp Biosciences and Population Health Partners launched Areteia with enough cash to fund Phase III asthma trials and Qiming revealed new VC funds totaling $2.5bn and $700m.
Finance Watch: Patient Square Capital Raises Mega-Fund, Topping Out At $3.9bn
Private Company Edition: Patient Square’s private equity fund, which surpassed its $3bn fundraising goal, may invest broadly across health care but the firm already has invested heavily in biopharma. Also, investor Dimension launches with a $350m specialized VC fund and Alto increased its series B to $60m.
All Eyes On Amjevita, Amgen’s Humira Biosimilar And Sole 2023 Product Launch
The company launched Amjevita on the same day it announced fourth quarter 2022 earnings and provided 2023 guidance, upping the high-profile nature of the first-to-market US Humira biosimilar.